ArticleBriefings in bioinformatics2026
EPBAM: annotation-robust detection of alternative splicing events and a systematic benchmarking of current tools.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alternative splicing (AS) is a major driver of transcriptomic diversity, yet its computational analysis remains challenged by inconsistent event definitions across tools and by the sensitivity of quantification methods to annotation quality. Here, we present a comprehensive benchmark of seven AS detection tools-replicate Multivariate Analysis of Transcript Splicing (rMATS), Super-fast Pipeline for alternative splicing analysis, version 2 (SUPPA2), Modeling Alternative Junction Inclusion Quantification + Visualization Of Inferred Local splicing Alternatives (MAJIQ+VOILA), EventPointerST (EPST), Shiba, LeafCutter, and the newly introduced EventPointer BAM (EPBAM)-evaluated across three complementary datasets: reverse transcription PCR (RT-PCR) validated experiments, simulated data, and Lexogen Spike-In RNA Variant (SIRV). The inclusion of SIRV, which provide experimentally derived sequencing data with fully controlled ground truth, is central to our evaluation framework, enabling rigorous assessment of quantification accuracy under real technical conditions. We assess tool performance under three annotation scenarios-complete, incomplete, and overloaded-reflecting the annotation uncertainty commonly encountered in practice. EPBAM extends the EventPointer framework by enabling de novo event detection coupled with a coverage-corrected Ψ quantification strategy. Our results demonstrate that annotation quality substantially drives tool performance: annotation-dependent tools achieve peak accuracy under complete annotations, whereas EPBAM exhibits the most robust and consistent behaviour across annotation conditions, recovering unannotated events with low false discovery rates. No single tool dominates across all evaluation metrics, highlighting the importance of dataset diversity and standardized benchmarking practices for meaningful tool comparison in the AS field.
Indexed as
Identifiers
42847769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.